免疫检查点抑制剂相关心血管毒性:一项观察性、回顾性药物警戒研究
该观察性、回顾性药物警戒研究利用VigiBase数据库,对比ICIs组与全数据库的心血管不良事件报告,发现ICIs与心肌炎、心包疾病、血管炎(含颞动脉炎和风湿性多肌痛)报告增多相关,多数心血管irAEs严重,中心肌炎病死率达50%。
要点
- ICIs治疗与心肌炎、心包疾病、血管炎(含颞动脉炎、风湿性多肌痛)报告增多相关。
- 心血管irAEs多数严重(>80%),心肌炎病死率50%(61/122)。
- 心包疾病多见于肺癌患者,心肌炎和血管炎多见于黑色素瘤患者。
核心结论
- ICIs治疗可在开始后不久导致严重和致残的炎症性心血管irAEs。
- 除危及生命的心肌炎外,这些毒性还包括心包疾病和可能导致失明的颞动脉炎。
- 这些事件应在患者护理和联合临床试验设计(即不同免疫疗法联合以及免疫疗法与化疗联合)中加以考虑。
研究设计与样本
- 观察性、回顾性药物警戒研究,使用WHO全球个体病例安全报告数据库VigiBase。
- 比较接受ICIs患者(ICI亚组)与全数据库中心血管不良事件的报告。
- 纳入1967年11月14日至2018年1月2日期间根据MedDRA分组查询分类的所有心血管irAEs。
- 使用报告比值比(ROR)和信息成分(IC)评估关联,IC025>0视为显著。
- 研究注册号ClinicalTrials.gov NCT03387540。
主要发现
- ICIs组报告31 321例不良事件,全数据库报告16 343 451例不良事件。
- 与全数据库相比,ICIs治疗与心肌炎报告增多相关(全数据库5515例 vs ICIs 122例,ROR 11.21 [95% CI 9.36-13.43];IC025 3.20)。
- 与全数据库相比,ICIs治疗与心包疾病报告增多相关(12 800例 vs 95例,ROR 3.80 [95% CI 3.08-4.62];IC025 1.63)。
- 与全数据库相比,ICIs治疗与血管炎报告增多相关(33 289例 vs 82例,ROR 1.56 [95% CI 1.25-1.94];IC025 0.03),包括颞动脉炎(696例 vs 18例,ROR 12.99 [95% CI 8.12-20.77];IC025 2.59)和风湿性多肌痛(1709例 vs 16例,ROR 5.13 [95% CI 3.13-8.40];IC025 1.33)。
- 心包疾病在肺癌患者中报告更多(49/87例,56%),心肌炎(42/103例,41%)和血管炎(42/70例,60%)在黑色素瘤患者中报告更多(总体亚组比较χ2检验,p<0.0001)。
临床怎么用
- 作者认为,这些事件应在患者护理和联合临床试验设计(即不同免疫疗法联合以及免疫疗法与化疗联合)中加以考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) have substantially improved clinical outcomes in multiple cancer types and are increasingly being used in early disease settings and in combinations of different immunotherapies. However, ICIs can also cause severe or fatal immune-related adverse-events (irAEs). We aimed to identify and characterise cardiovascular irAEs that are significantly associated with ICIs. METHODS: In this observational, retrospective, pharmacovigilance study, we used VigiBase, WHO's global database of individual case safety reports, to compare cardiovascular adverse event reporting in patients who received ICIs (ICI subgroup) with this reporting in the full database. This study included all cardiovascular irAEs classified by group queries according to the Medical Dictionary for Regulatory Activities, between inception on Nov 14, 1967, and Jan 2, 2018. We evaluated the association between ICIs and cardiovascular adverse events using the reporting odds ratio (ROR) and the information component (IC). IC is an indicator value for disproportionate Bayesian reporting that compares observed and expected values to find associations between drugs and adverse events. IC025 is the lower end of the IC 95% credibility interval, and an IC025 value of more than zero is deemed significant. This study is registered with ClinicalTrials.gov, number NCT03387540. FINDINGS: We identified 31 321 adverse events reported in patients who received ICIs and 16 343 451 adverse events reported in patients treated with any drugs (full database) in VigiBase. Compared with the full database, ICI treatment was associated with higher reporting of myocarditis (5515 reports for the full database vs 122 for ICIs, ROR 11·21 [95% CI 9·36-13·43]; IC025 3·20), pericardial diseases (12 800 vs 95, 3·80 [3·08-4·62]; IC025 1·63), and vasculitis (33 289 vs 82, 1·56 [1·25-1·94]; IC025 0·03), including temporal arteritis (696 vs 18, 12·99 [8·12-20·77]; IC025 2·59) and polymyalgia rheumatica (1709 vs 16, 5·13 [3·13-8·40]; IC025 1·33). Pericardial diseases were reported more often in patients with lung cancer (49 [56%] of 87 patients), whereas myocarditis (42 [41%] of 103 patients) and vasculitis (42 [60%] of 70 patients) were more commonly reported in patients with melanoma (χ2 test for overall subgroup comparison, p<0·0001). Vision was impaired in five (28%) of 18 patients with temporal arteritis. Cardiovascular irAEs were severe in the majority of cases (>80%), with death occurring in 61 (50%) of 122 myocarditis cases, 20 (21%) of 95 pericardial disease cases, and five (6%) of 82 vasculitis cases (χ2 test for overall comparison between pericardial diseases, myocarditis, and vasculitis, p<0·0001). INTERPRETATION: Treatment with ICIs can lead to severe and disabling inflammatory cardiovascular irAEs soon after commencement of therapy. In addition to life-threatening myocarditis, these toxicities include pericardial diseases and temporal arteritis with a risk of blindness. These events should be considered in patient care and in combination clinical trial designs (ie, combinations of different immunotherapies as well as immunotherapies and chemotherapy). FUNDING: The Cancer Institut Thématique Multi-Organisme of the French National Alliance for Life and Health Sciences (AVIESAN) Plan Cancer 2014-2019; US National Cancer Institute, National Institutes of Health; the James C. Bradford Jr. Melanoma Fund; and the Melanoma Research Foundation.
引用
- Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018. PMID: 30442497. doi:10.1016/S1470-2045(18)30608-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。